Stocks › Biotechnology › AURA

Aura Biosciences AURA

US equityMarket cap rank #3539Biotechnology

$6.46 +$0.29 (+4.70%)

Pre-market · Oct 8, 8:10 am ET · After hours $6.46 0.00%

Open$6.10

Prev close$6.17

Day range$6.10 – $6.56

Volume723.7K

Market cap$669.93M

P/E (TTM)–

Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership94.2%+0.74 pts vs. prior quarter

Institutions holding178-1 vs. prior quarter

Insider trades (recent)35 buys / 15 sellsNet buying

Short interest6.80% of floatDays to cover 11.7 · as of 15 Sep 2026

Short-sale volume share23.1%5-day average of daily volume

Short-sale volume as % of daily volume

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$93.6K (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 31.8% of shares outstanding.

Largest holders

TCG Crossover Management, LLC9.19%
Montanova Capital, LLC6.95%
Frazier Life Sciences Management, LP5.62%
Forbion Capital Partners B.V.5.06%
Long Focus Capital Management LLC4.94%
Vanguard Capital Management, LLC4.57%
BlackRock4.54%
Adage Capital Management, L.P.4.47%

By investor type

Hedge Fund35.67%
VC/PE Fund33.82%
Mutual Fund23.59%
Individual/Insider1.20%
Public Company0.69%
Private Company0.27%
Insurance Company0.08%
Family Office/Trust0.06%

Reported short interest has risen from 6.70% to 6.80% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

Holder	Type	Period	Share change	New stake
Forbion Capital Partners B.V.	VC/PE Fund	2026/Q3	+1,195,066	5.1%
TCG Crossover Management, LLC	VC/PE Fund	2026/Q3	+9,533,333	9.2%
Caligan Partners, LP	Hedge Fund	2026/Q3	+4,068,384	4.1%
OrbiMed Advisors LLC	VC/PE Fund	2026/Q3	+3,333,333	3.2%
Montanova Capital, LLC	Hedge Fund	2026/Q3	+2,833,333	6.9%
RA Capital Management, L.P.	VC/PE Fund	2026/Q3	+2,500,000	2.4%
Janus Henderson Group plc	Mutual Fund	2026/Q3	+2,500,000	2.4%
Vanguard Capital Management, LLC	Mutual Fund	2026/Q3	+2,096,558	4.6%
Balyasny Asset Management L.P.	Hedge Fund	2026/Q3	+1,796,965	2.3%
Redmile Group, LLC	Hedge Fund	2026/Q3	+1,666,667	1.6%
EcoR1 Capital, LLC	Hedge Fund	2026/Q3	+1,666,667	1.6%
Trails Edge Capital Partners, LP	Hedge Fund	2026/Q3	+1,443,333	1.4%
Foresite Capital Management, LLC	VC/PE Fund	2026/Q3	+1,333,334	1.3%
Woodline Partners LP	Hedge Fund	2026/Q3	+1,210,183	1.2%
Bellevue Asset Management AG	Mutual Fund	2026/Q3	+1,166,667	1.1%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

Date	Insider	Title	Transaction	Shares	Price	Held after
31 Aug 2026	Julie Person	Chief Human Resources Officer	Other Acquisition	+107,611	–	107,611
31 Aug 2026	Julie Person	Chief Human Resources Officer	Other Derivative Acquisition	+212,389	$7.43	212,389
31 Aug 2026	Erica Kratz	Chief Regulatory & Quality Officer	Other Acquisition	+100,885	–	100,885
31 Aug 2026	Erica Kratz	Chief Regulatory & Quality Officer	Other Derivative Acquisition	+199,115	$7.43	199,115
31 Aug 2026	J. Hopkins	Chief Medical Officer & President of Research and Development	Other Acquisition	+58,850	–	60,050
31 Aug 2026	J. Hopkins	Chief Medical Officer & President of Research and Development	Other Derivative Acquisition	+116,150	$7.43	116,150
31 Aug 2026	Amy Elazzouzi	Interim Principal Financial Officer & Interim Principal Accounting Officer	Other Acquisition	+23,540	–	143,600
31 Aug 2026	Amy Elazzouzi	Interim Principal Financial Officer & Interim Principal Accounting Officer	Other Derivative Acquisition	+46,460	$7.43	46,460
6 Jul 2026	Jeremy Bender	Independent Director	Other Acquisition	+30,000	–	30,000
6 Jul 2026	Jeremy Bender	Independent Director	Other Derivative Acquisition	+60,000	$7.03	60,000
30 Jun 2026	Conor Kilroy	General Counsel	Other Acquisition	+14,858	–	193,053
15 Jun 2026	Anthony Gibney	Chief Financial & Business Officer	Open Market Disposition	-12,824	$6.42	81,609
10 Jun 2026	Sapna Srivastava	Independent Director	Other Acquisition	+15,000	–	15,000
10 Jun 2026	Sapna Srivastava	Independent Director	Other Derivative Acquisition	+30,000	$6.21	30,000
10 Jun 2026	Antony Mattessich	Independent Director	Other Acquisition	+15,000	–	15,000
10 Jun 2026	Antony Mattessich	Independent Director	Other Derivative Acquisition	+30,000	$6.21	30,000
10 Jun 2026	David Johnson	Independent Chairperson	Other Acquisition	+15,000	–	15,000
10 Jun 2026	David Johnson	Independent Chairperson	Other Derivative Acquisition	+30,000	$6.21	30,000
10 Jun 2026	Teresa Marie Bitetti	Director	Other Acquisition	+15,000	–	29,000
10 Jun 2026	Teresa Marie Bitetti	Director	Other Derivative Acquisition	+30,000	$6.21	30,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report date	Shares short	% of float	Days to cover
15 Sep 2026	7,049,973	6.8%	11.7
31 Aug 2026	6,203,498	6.0%	6.4
14 Aug 2026	6,158,945	5.9%	9.9
31 Jul 2026	6,358,049	6.1%	18.5
15 Jul 2026	5,608,945	5.4%	8.1
30 Jun 2026	6,932,229	6.7%	9.3

Discussion

No comments yet — be the first to weigh in on AURA.